ReviewFrontiers in cardiovascular medicine2026
Protein lactylation in myocardial ischemia-reperfusion injury: mechanisms and therapeutic potential.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial ischemia-reperfusion injury (MIRI) remains a major unresolved problem in cardiovascular medicine. It commonly occurs in coronary heart disease (CHD) patients following reperfusion therapy or cardiopulmonary bypass (CPB)-assisted cardiac surgery. Despite the clinical necessity of restoring blood flow, reperfusion itself paradoxically exacerbates myocardial injury. The resulting therapeutic dilemma underscores the need for innovative cardioprotective strategies. Recent studies suggest that protein lactylation (Kla), a newly identified post-translational modification (PTM) derived from lactate metabolism, plays a crucial role in cardiomyocytes by regulating metabolic adaptation, injury repair, stress responses, cell death, and cardiac remodeling. However, there is still no comprehensive synthesis of the role of Kla in MIRI. In this review, we critically examine the emerging evidence linking Kla to the pathogenesis of MIRI and further discuss potential therapeutic strategies targeting this epigenetic mechanism to alleviate reperfusion-induced myocardial injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.